OUTLOOK: Long Road Ahead For Korean Pharma Globalization (Part 2)
This article was originally published in PharmAsia News
It’s been years since South Korea picked the pharma industry as a new growth engine and initiated the drive for globalization, setting a goal to push up the country’s pharma status to the world’s top seven by 2020 and vowing to provide strong assistance along the way. But there is still some distance to go.
You may also be interested in...
HanAll and Daewoong remain upbeat on dry eye candidate HL036 and are gearing up for a second Phase III US study despite the first missing its primary endpoint in just-released top-line results.
Among the Korean firms presenting at J.P. Morgan, Hanmi laid out its strategy for obesity and other core pipeline assets, Celltrion focused on its expanding biosimilar pipeline and China plans and LG Chem unveiled new R&D progress.
BeiGene licenses antibody therapeutics for Castleman’s disease and high-risk neuroblastoma.